Skip Ribbon Commands
Skip to main content

​​​

James Trotter, MD, Medical Director, Transplant Hepatology at Baylor University Medical Center is one of the chief investigators of a new therapy that could revolutionize how fatty liver disease is managed. According to the American Liver Foundation, 60 million Americans are living with nonalcoholic steatoheaptitis (NASH) which is a part of a group of conditions that lead to fat buildup in the liver, inflammation and fibrosis. Early results were just published in The Lancet, one of the highest ranked medicine journals in the world.

Read More

​​​​